… In patients with newly diagnosed type 2 diabetes in whom insulin therapy is not indicated, I
recommend that pharmacologic therapy with either a sulfonylurea or metformin be initiated as …

ContextCare of patients with type 2 diabetes has been … available oral agents for type 2
diabetes. Bibliographies were also … for the treatment of type 2 diabetes. Compared with placebo …

… The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral
therapy of type 2 diabetic patients… Diabetes Care. 2003;26(11):3080-3086.PubMed…

… Thus, to recapitulate, given its cost-effectiveness, we consider NPH insulin the preferred
agent for the initiation of insulin therapy in type 2 diabetes. However, if dose titration is limited by …

… of type 2 diabetes is not well defined.ObjectiveTo assess the efficacy and safety of incretin-based
therapy in adults with type 2 diabetes … incretin therapy with placebo or other diabetes …

… associated with Type 2 diabetes and discusses the benefits of exercise therapy on phenotype
characteristics, glycemic control and cardiovascular risk profile in Type 2 diabetes patients…

… deficiency, whereas type 2 diabetes is a … of type 1 and type 2 diabetes differs, medical
nutrition therapy (MNT) goals for both are similar. MNT plays a critical role in managing diabetes …

… of type 2 diabetes, there is … therapy to achieve optimal glucose control. This article discusses
the rationale and indications for insulin treatment therapy in patients with type 2 diabetes …

… We randomly assigned 5518 patients with type 2 diabetes who were being treated with
open-label simvastatin to receive either masked fenofibrate or placebo. The primary outcome …

… the general principles of drug therapy in patients with type 2 (non-insulin—dependent)
diabetes mellitus. In addition, a rational approach to drug therapy will be suggested along with …